Edition:
India

Regeneron Announces Updated Libtayo Results In Advanced Cutaneous Squamous Cell Carcinoma


Thursday, 16 May 2019 

May 16 (Reuters) - Regeneron Pharmaceuticals Inc ::UPDATED LIBTAYO® (CEMIPLIMAB-RWLC) RESULTS REINFORCE DURABLE AND SUBSTANTIAL RESPONSE RATES IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA.REGENERON PHARMACEUTICALS INC - NEW DATA AT ASCO INCLUDE MORE THAN DOUBLE PATIENTS PREVIOUSLY REPORTED.REGENERON PHARMACEUTICALS INC - MEDIAN OVERALL SURVIVAL STILL NOT REACHED WITH A MEDIAN FOLLOW-UP OF UP TO 17 MONTHS IN STUDY.